SAB Biotherapeutics (SABS) Stock Forecast & Price Target

SAB Biotherapeutics is positioned favorably because the FDA’s accelerated approval of Tzield in Stage 3 T1D validates C-peptide preservation as an approvable surrogate endpoint, directly de-risking SAB-142’s ongoing potentially pivotal SAFEGUARD trial. The company’s lead asset also appears differentiated by early data suggesting low immunogenicity, no serum sickness, no neutropenia, and a repeat-dosing profile that could be more practical than Tzield’s 14-day IV regimen, while addressing a large unmet need in a market with ~1.5mn people living with T1D in the U.S. and ~64k new cases per year. Financially, the bullish case is reinforced by modeling that assigns SAB-142 a 60% probability of success and projects ~$2.4bn in 2035 revenues, supported by a broad development-stage portfolio and multiple upcoming catalysts.

SAB Biotherapeutics is a highly speculative clinical-stage company whose fundamental weakness is near-total dependence on SAB-142, making the investment case vulnerable to any setback in safety, efficacy, or regulatory review. The FDA stopped short of a broader label when key secondary endpoints of PROTECT failed to show reduced HbA1c or lower insulin use, reinforcing concerns that the pipeline may not translate into meaningful commercial benefit despite the company’s disease-modifying thesis. With a history of losses, expected significant operating losses, limited human data, no sales or distribution infrastructure, and added herd, IP, and competitive risks, it may need dilutive financing just to continue development.